



PRECISEU

Call Document

PRECISEU Best Practice Recognition

Edition 3, Version 01

This project has received funding from the European Union's Horizon Europe research and innovation programme under Grant Agreement No 101161301

CONTENT

1.	Introduction.....	4
2.	Background.....	5
3.	Objectives — Themes and priorities — Activities— Expected results	5
	Objectives.....	5
	Themes and priorities.....	6
	Categories.....	7
	Expected outcomes	9
	Expected results	9
4.	Benefits.....	9
5.	Timetable and deadlines	10
6.	Admissibility and documents.....	10
7.	Eligibility	10
	Eligible participants (eligible countries).....	10
	Eligibility conditions.....	11
	Eligible activities	12
	Ethics and values	12
	Verification	12
8.	Exclusion	13
9.	Evaluation and Recognition procedure	14
10.	PRECISEU Best Practice Recognition criteria	15
11.	Other conditions.....	15
	Reward	15
	Communication — Dissemination — Visibility of funding.....	15
	IPR — Rights of use.....	16
	Checks, audits and investigations.....	16
	Withdrawal of the Recognition	17
12.	How to submit an application	17
	General information and Privacy Policy	17
	Project related information.....	17
	Deadline and Platform.....	17
	Submission System Requirements	17
	Project and Category Guidelines	18
	Additional Requirements.....	18
13.	Help	19
	Contact	19



Changes

Chapter	Version 1	Version 2 for Edition 2
3. Objectives-categories	INNOVATION: SMEs and Startups that are revolutionizing....	INNOVATION: Organizations that are revolutionizing...
5 Timetable		New dates for 2 nd edition
10 Other conditions - reward	The applicants will be informed in July 2025 if they are amongst the 12 finalists. The winning organizations will be informed in August and announced in September 2025, provided all the requested documents have been submitted. The winners will be asked to attend the Life Sciences Baltics Conference in 2025, Vilnius. Special conditions apply, e.g. reduced registration fees and reduced hotel costs. The Recognition Ceremony will take place on 18 September 2025 at the Life Science Baltics Conference, Vilnius.	dates and Location for Ceremony adjusted to 2nd Edition
10 Other conditions - dissemination	Reference to Grant No	Use disclaimer
	Version 2 for Edition 2	Version 3 for Edition 2
5 Timetable		dates for 2 nd edition
7 Eligibility - eligibility conditions	INNOVATION: They are groundbreaking in the sense of originality and creativity in the application of health data.	INNOVATION: They are groundbreaking in the sense of originality and creativity in the application of health data and ATMP technologies
3 Objectives-Themes and priorities — Activities— Expected results-Categories	INNOVATION: Organizations that are revolutionizing patient care in the field of ATMPs through breakthrough innovations, leveraging patient data to drive transformative solutions.	INNOVATION: Organizations that are revolutionizing patient care in the field of ATMPs through breakthrough innovations <u>and</u> leveraging patient data to drive transformative solutions.
9 Evaluation and Recognition procedure	Three finalists in each category will be announced in July. Jury members will decide afterwards who will receive the recognition. The winner will be informed in July and announced in September.	Three finalists in each category will be announced in May . Jury members will decide afterwards who will receive the recognition. The winner will be informed in May and announced in June .
10 PRECISEU Best Practice Recognition criteria	Innovation: Originality and creativity in the application of health data.	Innovation: Originality and creativity in the application of health data and ATMPs .
5 timelines	1 March 2026	12 March 2026 (extended)
	Version 3 or Edition 2	Version 4 for Edition 3
3, 8		New call with new criteria for the categories having impact on section 3, 8 and minor changes in other sections
5, 9 Timetable and Evaluation and Recognition procedure		dates for 3 rd edition

1. Introduction

The PRECISEU Best Practice Recognition is a promotion designed to inspire, motivate, and showcase exemplary practices in healthcare, particularly in the innovative ATMP development and use of health data.

This contest operates under the *PeRsonalised medicine Empowerment Connecting Innovation ecoSystems across EUrope* (PRECISEU) Programme. PRECISEU is co-funded by the European Union's Horizon Europe research and innovation programme under Grant Agreement No 101161301 as part of the New European Innovation Agenda, and capitalizes on the potential of deep-tech innovation in the different territories of the EU.

We encourage all participants to carefully review this document, which provides valuable guidance and answers to support the preparation of your application.

These documents provide clarifications and answers to questions you may have when preparing your application:

the Call Document (Rules of Contest) outlines the:

- Background (section 1 and 2)
- objectives, scope, activities that can be recognized and the expected results (section 3)
- benefits and available timetable (section 4 and 5)
- admissibility and eligibility conditions (including mandatory documents; section 6 and 7)
- criteria for exclusion (section 8)
- evaluation and selection process, recognition procedure (section 9)
- recognition criteria (section 10)
- other conditions (section 11)
- how to submit an application (section 12)

2. Background

PRECISEU is a flagship project of the European Commission's Horizon Europe Program that will address the main challenges of Personalised Medicine in Europe defined in the Strategic Research & Innovation Agenda (SRIA) agreed upon by experts from the large European consortium EP Permed. PRECISEU will contribute to achieving the goals of a more preventive, personalised, predictive, patient-centered, and participatory medicine (5P) in a shorter time.

The consortium includes regional authorities, clusters, a European Research Infrastructure Consortium, global pharmaceutical companies, patient organizations, and European Digital Innovation Hubs. The project has a budget of 23 million euros and will run for five years, until June 30, 2029.

The general objective of PRECISEU is to increase the efficiency of the regional innovation ecosystems through strengthened collaboration and shared resources on strategic areas of regional strength and specialization, enabling the development and implementation of innovating initiatives, and facilitating the digital and sustainable transformation of healthcare systems.

3. Objectives — Themes and priorities — Activities— Expected results

Objectives

PRECISEU is an initiative dedicated to connecting innovation ecosystems across Europe, with a focus on advancing personalised healthcare. Despite recent success in personalised medicine, significant barriers still hinder a broader rollout of these technologies. Challenges are the access and use of health data in harmonized systems and the costs of the treatments that stress healthcare systems across Europe.

PRECISEU systematically screened for additional, regional barriers. Major hurdles seen across Europe were identified and published in the findings in PRECISEU D6.1 Cross Regional Report, Sahlgrenska Science Park, Gwen Gilderson (2025). Besides the well-known technical and regulatory hurdles, also ecosystem and structural burdens were identified.

The PRECISEU Best Practice Recognition aims to address these challenges by providing Europe-wide promotion for the most innovative and successful solutions in overcoming these obstacles. By showcasing and transferring best practices between regions, the PRECISEU Best Practice Recognition accelerates progress toward truly personalised healthcare. It also promotes the scaling-up of deep-tech healthcare innovations, particularly those based on advanced therapy medicinal products and the strategic use of health data. Ultimately, PRECISEU seeks to strengthen connectivity among regional ecosystems across Europe, fostering collaboration and innovation for a healthier future.

Themes and priorities

The research performed by PRECISEU uncovered a frequent set of obstacles that stand in the way of fast implementation of personalised and precision care. They can be structured into the following four consolidated themes:

Technical and infrastructural constraints

Personalised therapies are inherently complex processes that are difficult to scale. They require intensive patient stratification and highly specialized expertise for manufacturing treatment products. This results in high costs for both testing and therapy. These challenges are amplified by healthcare infrastructure and capacity limitations: rural and non-academic centers often lack the necessary equipment, logistics, certification and skilled staff to deliver precision medicines in an equitable manner. This reinforces centralization of care and deepens geographic disparities in access. Consequently, market uptake of novel therapies is slowed.

Market access, reimbursement and regulatory complexity

Even when ATMPs reach clinical maturity, high costs of therapies combined with opaque, fragmented or outdated reimbursement models slow market uptake and restrict access. It often is unclear what exactly can be reimbursed, by whom, and under which conditions. In addition, legal, regulatory and bureaucratic complexity, spanning GDPR, ATMP-specific rules, AI regulation and secondary data use, creates uncertainty and delay. In Europe, these fragmented, time-consuming regimes and high administrative burden prolong clinical trial applications and approvals, they complicate cross-border activities and hinder timely data use, thereby delaying both validation of the technology and market access.

Data, interoperability, governance and AI

Non-interoperable and siloed data still prevent the efficient and lawful reuse of health data for precision medicine. Health data cannot be used efficiently for personalised medicine, AI, and research across institutions and borders. The absence of AI algorithm validation frameworks results in limited trust in AI of clinicians and patients and is leading to slow AI adoption in clinical workflows despite the given scientific strength.

Skills, ethics, patient engagement and coordination

On the cultural and organizational level, competence and coordination gaps further limit the adoption of personalised medicine. Across Europe, there is an uneven distribution of expert clinicians as well as bioinformatics and AI literacy. This lack of technically skilled staff often is accompanied by a shortage of structured, national-level training programs and ATMP-specific competence centers. Fast implementation of personalised medicinal products requires coordinated ecosystems and targeted skill development of professional personnel. Structured training and staff education are needed to establish the framework for access to novel therapies.

When it comes to implementation of AI, a lack of structured training of experts and public engagement leads to ethical and societal concerns among patients and clinicians. This includes

fear of discrimination. Trust-building activities and educational programs are not even distributed across Europe.

Categories

PRECISEU aims to create a roadmap to enable faster implementation and procurement of innovations within precision care, focusing on reimbursement, regulatory pathways, health data, clinical implementation, and ecosystem capacity. Approaches that can be adopted across health systems to accelerate equitable and sustainable patient access to transformative therapies can be highlighted and included as part of this roadmap. The four prize categories (IMPACT, INNOVATION, EXCELLENCE, CULTURE) are designed to collect and recognize best practices that directly tackle the consolidated challenges and provide concrete, transferable solutions that help to build more harmonized systems across Europe.

We call for applications from organizations that have developed solutions addressing challenges in one of the four groups. The PRECISEU Best Practice Recognition will be awarded to organizations in one of the following categories:

INNOVATION – Breakthrough technologies and cost-lowering solutions

Solutions sought in this category address the **technical and economic challenges** of complex, costly, and difficult-to-scale advanced therapy medicinal products (ATMPs) and personalised treatments, including their development and manufacturing.

This category focuses on organizations that are revolutionizing patient care through breakthrough innovations that are distinguished by **simplicity of adoption and/or lower production costs**. Projects must demonstrate novelty and utility, ideally evidenced by a patent application or other intellectual property, such as know-how derived from the project.

Innovations can range from new ATMP modalities (e.g., cell and gene therapies, organoids, engineered tissues) to tools and processes that significantly reduce development and production costs or mitigate risks in technology transfer. Projects are considered groundbreaking if they show originality and creativity in ATMP technologies or substantially reduce the financial and operational pressure on healthcare systems while maintaining or improving outcomes. Models of effective infrastructure or services that lead to transferable implementation practices are also welcome to apply, including shared manufacturing capacity, access to GMP facilities, logistics solutions, and innovative technology-transfer models for personalised medicine products.

IMPACT – Transformative market access and sustainable real-world benefit

This category seeks concrete best practices that overcome opaque and fragmented reimbursement rules, as well as legal and regulatory complexity, to bring clinically mature ATMPs and related innovations into reimbursed and routine care.

Eligible organizations should demonstrate how a novel tool, model, or approach has successfully opened a novel **pathway for regulation-to-market access**. These tools can include advanced therapies that have reached the market, or diagnostics and digital solutions that support personalised patient care. The **project has effectively navigated complex frameworks** (e.g.,

GDPR, ATMP-specific regulation) to reduce delays and administrative burden. Projects can show evidence-based improvements in patient access to personalised medicinal products. They can document their streamlined clinical trial and approval processes and clear pathway to reimbursement or smarter cross-border and data-use strategies that have accelerated market uptake and has generated real-world evidence.

Projects in this category set a benchmark for how to turn regulatory and market access barriers into transparent, predictable, and equitable pathways for personalised medicines adoption.

EXCELLENCE – Health data and AI excellence for personalised medicine

Solutions sought in this category address the challenges of siloed data, limited interoperability, heterogeneous governance, and **trust building** in AI deployment for precision medicine.

This category recognizes organizations that **exemplify health data excellence**. They operationalize patient data for personalised medicine under FAIR data principles with inclusivity being striven. Applicants are expected to demonstrate mature and transparent pathways for data access and coordinated data-access governance for collaborations, in best case with cross-institutional, cross-border consent in practice. These can be clearly visible in project landing pages, designated contact points, and well-documented access procedures. Standardized frameworks enable seamless data integration and harmonization across institutions, technologies, and data types are implemented. They should show robust quality control for raw data input, including systematic documentation, curation, and clinically meaningful stratification, as well as strict adherence to state-of-the-art requirements for data security, privacy, and ethical handling of patient information.

When it comes to implementation of AI, regulatory expectations and governance requirements for trustworthy AI must be fulfilled, including mechanisms for accountability, transparency, explainability, and continuous monitoring of bias and performance. Submissions are expected to highlight how this integrated approach to health data management and trusted AI implementation enables innovation while safeguarding trust, inclusivity, and excellence, and to demonstrate how the underlying practices, tools, and governance models can be replicated, adapted, or scaled across other settings and ecosystems.

CULTURE – Patient involvement, public engagement and cultural impact

Solutions sought in this category address gaps in skills, ethics and coordination surrounding the use of health data, AI and novel therapies. The focus lies in fostering a culture of trust through transparency and well-informed collaboration between caregivers, health data stakeholders and the broader public.

This category recognizes organizations that have developed tools to build multidisciplinary **competence and awareness** among stakeholders. Professional training is translated into practice alongside meaningful patient involvement and public engagement. Projects clearly share how they were started and implemented within their ecosystems, describing which partners were involved and which skills, resources and training were required.

It is beneficiary if patient perspectives and public engagement are integrated into the design, execution, and evaluation of initiatives, with explicit attention to the inclusion of diverse and underserved communities. Approaches may include education and skill development of clinical experts, co-creation with patients in planning and decision-making (for example, patient advisory boards, co-designed materials and participatory governance structures) and transparent, understandable communication about benefits, risks in data use and/or AI implementation. Projects are expected to demonstrate measurable benefits, such as improved trust, understanding, acceptance, public participation and transferable best practices for adapting these infrastructures to other ecosystems and regions. These projects serve as benchmarks for cultural change, illustrating how strong communication and inclusive processes enable the responsible and equitable adoption of personalised medicines.

Expected outcomes

Create a collection of solutions for recurrent problems in personalised medicine. Enable the implementation of best practice models in Europe by highlighting the promoted examples. By creating a European network of excellence, the introduction of personalised medicine will be accelerated and improve healthcare outcomes.

Expected results

The PRECISEU Best Practice Recognitions will drive positive changes within innovators, policymakers, patients, SMEs and healthcare organizations and foster the culture of deep tech within health care regarding resistance and skepticism while encouraging the adoption of innovative approaches. The PRECISEU Best Practice Recognitions should recognize the commitment of individuals or teams that lead to the advancement of personalised medicine, to inspire and advocate for the broader adoption of the model.

4. Benefits

Each winner will be featured prominently across social media platforms associated with the organization, reaching a diverse and engaged audience. This includes targeted promotion to raise awareness of their achievements in Europe and beyond, showcasing their success on a global stage. This widespread European and international promotion is an opportunity to connect with key stakeholders, professionals, and decision-makers in their field.

The winners are invited to join with up to two individuals events hosted by a PRECISEU network member. This includes the opportunity to be celebrated on stage in a Recognition Ceremony and being showcased among an esteemed audience of peers and industry leaders.

As part of their promotion, the winner will have the unique opportunity to contribute their insights and knowledge by participating in high-level sessions for decision-makers. This platform allows the winner to interact with policy, being a role model for industry practices, and solidify their reputation as a thought leader in their domain. Participation in roundtables, workshops and expert discussions will be offered depending on availability and fit for purpose within the PRECISEU network.

5. Timetable and deadlines

<i>Timetable and Deadlines</i>	
Call opening	October 2026
Deadline for Submission	28 February 2027
Evaluation	End of the period: 31. March 2027
Notification to finalists and winners	April 2027
Announcement of finalists	May 2027
Public voting (optional)*	03 – 19 May 2027
Recognition Ceremony	25 May 2027

- *Depending on the number of incoming applications

6. Admissibility and documents

Applications must be submitted before the call deadline (see timetable in section 5).

Applications must be submitted electronically via the questionnaire provided on the PRECISEU website. Paper submissions are NOT possible.

Applications (including annexes and supporting documents) must be submitted using the submission system or as requested.

All information provided must be in English.

Your application must be readable, accessible and printable.

An applicant can apply with clearly separatable projects for PRECISEU Best Practice Recognition.

In case you are amongst the finalists, you will be asked at a later stage for further documents and a five-minute video presentation of your project. The winner will be expected to attend the Recognition Ceremony. They will be asked for statements or a short video message on the achievements in the allocated category. These materials will be used for communication and promotion purposes only.

7. Eligibility

Eligible participants (eligible countries)

In order to be eligible, the applicant must:

- be a legal entity (public or private body)
- be research performing organization, including a higher education establishment (e.g. university)
- be established in one of the eligible countries, i.e.:
 - o EU Member State (including overseas countries and territories (OCTs))
 - o non-EU country associated to the Horizon Europe (associated countries)

- comply with the mandatory requirements of the PRECISEU Best Practice Recognition eligibility criteria

Applicants cannot receive a second recognition for the same activities, including previous Editions of the PRECISEU Best Practice Recognitions. Independent projects from previous winners can be honored.

Eligibility conditions

Organizations apply with a published project and will not share confidential information.

A project

- can be an infrastructure (but not limited to) implemented to teach, optimize communication, or train the public or experts from research or policy making about personalised medicine and health data use. If such a project is the implementation of new tools of impact, e.g. landing page, infrastructure, personnel with scientific project supportive tasks, it must be implemented and successfully running, preferably with traceable traction.
- is an innovative, scientific project or clinical trial and must have reached TLR6.

The projects submitted must not be funded under the PRECISEU programme and, accordingly, must not receive any funding from the European Union's 'Horizon Europe' research and innovation programme under Grant Agreement No 101161301. This means that they e.g. must not be one of the joint interregional projects (JIPs), nor must they relate to infrastructure or technology provided by PRECISEU itself for such collaborations.

Applicants must have published in the past two years such a **project that supports or involves**

A) uses of **health data** for public health improvement or healthcare delivery, **AND**

B) innovations in the fields of **advanced therapeutics**. This topic is used as a broad, technology-neutral umbrella and includes:

- Advanced Therapy Medicinal Products (ATMPs) as defined in EU legislation (gene therapy medicinal products, somatic cell therapy medicinal products, tissue engineered products, and combined ATMPs).
- RNA-based therapies and other advanced nucleic-acid-based therapeutics, including non-coding RNA therapies (e.g., antisense oligonucleotides, siRNA/RNAi, miRNA/lncRNA-based approaches and related modalities), regardless of whether they are classified as ATMPs or as chemically synthesised medicinal products.
- Enabling technologies that are integral to the translation of these therapies towards TRL 6 (e.g., delivery/formulation integral to the therapy, GMP/manufacturing scale-up, analytical/potency methods, comparability strategies, and regulatory/HTA interaction activities), provided the project's centre of gravity remains on advancing a "Medicines for Novel Therapies" modality.

Publishing in this context means at least one of the following: publication in a peer reviewed paper, initiation of clinical trial, a homepage that provides public access to data infrastructure, or launched a patient resp. public engagement project.

The information shared by the applicants must enable the jury to see the potential of the project and highlight outstanding achievements. The evaluation will only be based on the description shared and uploaded in the application form. Information from additional materials, e.g. websites, publications, etc. will not be fully reviewed and are used to support quality and eligibility.

Upon request, applicants must verify their legal status. For validation, you will be requested to upload documents showing legal status and origin.

Eligible activities

Eligible activities are the ones set out in section 7 above.

Ethics and values

Activities must comply with the highest ethical standards and the applicable EU, international and national law on ethical principles. Moreover, they must respect basic EU values (such as respect for human dignity, freedom, democracy, equality, the rule of law and human rights, including the rights of minorities).

The activities must comply with:

- ethical principles (including the highest standards of research integrity) and
- applicable international, EU and national law

and may not:

- aim at human cloning for reproductive purposes
- intend to modify the genetic heritage of human beings which could make such changes heritable (except for research relating to cancer treatment of the gonads which may be financed), or
- intend to create human embryos solely for the purpose of research or for the purpose of stem cell procurement, including by means of somatic cell nuclear transfer.

Moreover, activities must have an exclusive focus on civil applications, and no recognition can be awarded for activities carried out outside the EU, if they are prohibited in all Member States.

Verification

In case of entering the round of the three best applications in one category, we may ask for additional documents like:

Legal Entity Validation Documents:

- SMEs and Startups: provide a self-declaration that the company is sustainable and will be in operation at least for three months after the recognition

Ethics Review Documents:

- Ethics approval certificates for any data collection or clinical trials involved in your project.
- Documentation of compliance with data protection regulations (e.g., GDPR compliance statement).

Declaration of Honour:

- A signed declaration confirming the accuracy of the submitted information and adherence to the recognition's ethical and procedural standards.

8. Exclusion

Applicants which are subject to an EU exclusion decision or in one of the following exclusion situations that bar them from receiving EU funding can NOT participate:

- bankruptcy, winding up, affairs administered by the courts, arrangements with creditors, suspended business activities or other similar procedures (including procedures for persons with unlimited liability for the applicant's debts)
- in breach of social security or tax obligations (including if done by persons with unlimited liability for the applicant's debts)
- guilty of grave professional misconduct²⁴ (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the implementation of the Recognition)
- committed fraud, corruption, links to a criminal organization, money laundering, terrorism-related crimes (including terrorism financing), child labor or human trafficking during the Recognition procedure they misrepresented information required as a (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the implementation of the Recognition)
- shown significant deficiencies in complying with main obligations under an EU procurement contract, grant agreement, prize, expert contract, or similar (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the implementation of the Recognition)
- guilty of irregularities within the meaning of Article 1(2) of Regulation No 2988/95 (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the implementation of the Recognition) created under a different jurisdiction with the intent to circumvent fiscal, social or other legal obligations in the country of origin or created another entity with this purpose (including if done by persons having powers of representation, decision-

making or control, beneficial owners or persons who are essential for the implementation of the Recognition).

Applicants will also be refused if it turns out that:

- during the PRECISEU Best Practice Recognition procedure they misrepresented information required as a condition for participating or failed to supply that information
- they were previously directly involved in the preparation of the call, and this entails a distortion of competition that cannot be remedied otherwise (conflict of interest).

9. Evaluation and Recognition procedure

Applications will undergo a formal evaluation by a jury.

Non-confidential information, including project details and supporting documents (e.g., papers, links), will be shared with the jury.

If there are more than 90 applications in a prize category, a pre-selection will narrow it down to the top 30, which will then be reviewed by the jury. If fewer than 30 applications are received, all will be reviewed. Each jury member will review no more than ten applications.

The pre-selection panel and jury may have different members, although jury members can be part of the pre-selection panel.

The pre-selection panel/jury will evaluate each application against the recognition criteria.

For applications in each of the four categories, the pre-selection panel/jury will determine a priority order according to the following approach:

Several parameters are assessed across the four categories. The jury will score each parameter on a scale from -2 (improvement needed), through 0 (average), to +2 (excellent). The scores across all parameters will be combined to give a total score ranging from -10 to +10 points in each category.

If two or more applications achieve the maximum score in a category, a jury meeting will be held to determine the winner. The selected application will receive the Recognition in that category.

All winners will be informed in April and announced in May.

If enough high-quality applications in all categories are handed in: Based on the jury's evaluation (and subject to mandatory checks, including an ethics review, legal entity validation, and verification of non-exclusion criteria) the Recognizing Authority will select three finalists in each category. The finalists will be announced in May, followed by a public vote to determine the Public Favorite.

The final and public announcement will be during the PRECISEU Best Practice Ceremony, the winners are invited to join (s. 11. Other conditions, rewards).

10. PRECISEU Best Practice Recognition criteria

If admissible and eligible, all applications will be evaluated and ranked against the following Recognition Criteria defined for all the four Categories:

Do they overcome one of the four defined frequent hurdles of personalised medicine and can they be adopted in other settings across Europe.

For each category the following aspects are evaluated:

INNOVATION: This category focuses on novelty, originality, and practical utility, including the lowering of health care costs through the implementation of the tool described. Evidence of innovation, including the generation of some form of intellectual property (IP), will be required.

IMPACT: This category assesses how a project navigated the regulatory landscape successfully and translated research into practical applications and implementation.

EXCELLENCE: This category focuses on scientific and operational excellence in health data use, with particular emphasis on data integrity, quality assurance, and compliance with ethical standards to fulfill preparedness for EHDS and AI implementation.

CULTURE: This category evaluates the quality and impact of projects in developing knowledge, competencies, and practical skills in personalised medicine. Projects may target expert audiences, including healthcare professionals and researchers, or the public, with an emphasis on effective knowledge transfer and capacity building.

11. Other conditions

Reward

The applicants will be informed in April 2027 if they are amongst the 12 finalists. The winning organizations will be informed in April 2027 and announced in May 2027, provided all the requested documents have been submitted. The winners will be asked to attend the PRECISEU Best Practice Recognition Ceremony, held at the Vitalis congress, The leading Nordic event shaping the future of healthcare, happening from 24-27 May 2027 in Gothenburg, Sweden. The Ceremony will take place on May 25, in Gothenburg at Svenska Mässan.

Communication — Dissemination — Visibility of funding

Winners are invited to promote the PRECISEU Best Practice Recognition and its results, by providing targeted information to multiple audiences (including the media and the public) in a strategic and effective manner.

Communication activities related to the PRECISEU Best Practice Recognition (including media interviews, press statements, presentations, etc., in electronic form, via traditional or social media, etc.), must acknowledge EU support and display the European flag (emblem) and funding statement (translated into local languages, where appropriate) and PRECISEU logo:



**Co-funded by
the European Union**

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.



PRECISEU

The emblem must remain distinct and separate and cannot be modified by adding other visual marks, brands, or text.

Apart from the emblem and the PRECISEU logo, no other visual identity or logo may be used to highlight the EU support.

When displayed in association with other logos (e.g. of winners or sponsors), the emblem must be displayed at least as prominently and visibly as the other logos

For the purposes of these obligations, the winners may use the emblem or logo without first obtaining approval from the PRECISEU Best Practice Recognition authority. This does not, however, give them the right to exclusive use. Moreover, they may not appropriate the emblem or any similar trademark or logo, either by registration or by any other means.

Any communication or dissemination activity related to the PRECISEU Best Practice Recognition must use factually accurate information.

Moreover, it must indicate the following disclaimer (translated into local languages where appropriate):

IPR — Rights of use

The PRECISEU Best Practice Recognition authority does not obtain ownership of the results produced in the context of the Recognition.

The PRECISEU Best Practice Recognition authority has the right to use non-sensitive information relating to the Recognition and materials and documents received from the winners (such as pictures or audio-visual material, in paper or electronic form) for information, communication, dissemination and publicity purposes.

Photos and videos taken by the PRECISEU Best Practice Recognition Authority either in preparation of the Recognition Ceremony or during the Recognition Ceremony are the sole property of the PRECISEU Best Practice Recognition Authority.

Checks, audits and investigations

The PRECISEU Best Practice Recognition authority, the members of the PRECISEU-project may carry out checks and investigations in relation to the Recognition.



**Co-funded by
the European Union**

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.

Withdrawal of the Recognition

The PRECISEU Best Practice Recognition authority may withdraw the Recognition after its announcement, if it finds out that

- false information, fraud or corruption was used to obtain it
- the winners were not eligible or should have been excluded or
- the winners are in serious breach of their obligations under these Rules of Contest

12. How to submit an application

All applications must be submitted directly online via the PRECISEU registration portal. Paper applications are NOT accepted.

You can access the registration by clicking 'Apply: [here](#)' on the official PRECISEU Best Practice Recognition webpage.

General information and Privacy Policy

For organizational reasons, we will ask you about your institution and to upload personal information. This data will not go to the jury. By uploading this information, you agree that PRECISEU partners can handle the data according to their data protection policies.

Project related information

To evaluate if your project is outstanding in the sense of the Recognition Criteria, the jury members need information that describes your solution to existing problems in personalised medicine. Applicants are invited to hand in a description of the project. A form is provided and must be used. **PLEASE, SHARE NON-CONFIDENTIAL INFORMATION ONLY!** Share information you want to be distributed and copied for you to become a role model in best practice of health data use in ATMPs!

Deadline and Platform

- All applications must be submitted **before the call deadline**. Refer to the timetable in **Section 4** for the exact dates.
- Applications **must be submitted electronically** using the questionnaire on the PRECISEU platform.
- Paper submissions are NOT accepted.

Submission System Requirements

- Applications, including all annexes and supporting documents, must be submitted via the **Submission System**.
- All submitted information must be in English.
- Ensure your application is readable, accessible, and printable.

Project and Category Guidelines

- Applicants can apply to **only one category** of the prize categories per project.
- Published projects only: Applications must involve initiatives already published (e.g., peer-reviewed paper, initiated clinical trial, public data infrastructure).
- Applications must **not contain confidential information**.

Additional Requirements

When starting the application, the following documents and materials are available to expedite the process:

Supporting information to the project will be requested:

- Detailed project description, including:
 - Objectives, methods, and outcomes.
 - Information on scalability and sustainability.
- Evidence of project publication, such as:
 - Peer-reviewed journal articles.
 - Clinical trial registration details.
 - Publicly accessible webpages or platforms providing access to the project's data infrastructure.
 - Any patents, intellectual property (IP) documentation, or records of innovation where applicable.
 - Letters of support from partners, stakeholders, or collaborators.

By gathering all available materials beforehand, you can ensure a smoother and more efficient submission process.

For all categories, the same questionnaire will initially be started. For each category the survey will go into more detail according to the criteria of the resp. category.

The application must be submitted before the call deadline (see section 5). After this deadline, the system is closed, and applications can no longer be submitted.

Once the application is submitted, you will receive a confirmation e-mail (with the date and time of your application). This is not an automatic process. If you do not receive this confirmation e-mail, it means your application has NOT been submitted. If you believe this is due to a fault in the submission system, you should immediately file a complaint via the technical support contact, explaining the circumstances and attaching a copy of the application (and, if possible, screenshots to show what happened).

13. Help

Additional information can be found here:

- Supporting document “questionnaire”: you can pre-read the questionnaire to prepare for the upload of the requested information.
- PRECISEU website including an FAQ section

Contact

For individual questions on the application form, please

- **contact for technical support:**
Mireia Ros: mros@biocat.cat
- **Non-IT related questions please contact**
Daniela Weber: dw@biorn.org